Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by HC Wainwright to “Buy” Rating

Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by investment analysts at HC Wainwright to a “buy” rating in a research note issued on Monday, Marketbeat reports. The firm currently has a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 185.20% from the stock’s current price. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($5.14) EPS, Q1 2026 earnings at ($1.83) EPS, Q2 2026 earnings at ($1.59) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.05) EPS and FY2026 earnings at ($5.88) EPS.

RARE has been the topic of several other research reports. William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an “outperform” rating and a $65.00 target price on the stock. Morgan Stanley decreased their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Wells Fargo & Company decreased their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, July 10th. Guggenheim restated a “buy” rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, Wedbush decreased their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a report on Monday, July 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $82.57.

Ultragenyx Pharmaceutical Stock Up 1.4%

RARE stock traded up $0.39 during trading hours on Monday, hitting $28.05. The company’s stock had a trading volume of 246,495 shares, compared to its average volume of 1,244,379. The company has a market capitalization of $2.65 billion, a PE ratio of -4.77 and a beta of 0.26. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $60.37. The stock has a 50 day moving average price of $34.46 and a two-hundred day moving average price of $37.47.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business’s revenue was up 28.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.03) earnings per share. Sell-side analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $715,000. Nordea Investment Management AB raised its stake in shares of Ultragenyx Pharmaceutical by 59.8% in the 2nd quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company’s stock valued at $2,208,000 after buying an additional 22,509 shares in the last quarter. WCM Investment Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 4.1% in the 2nd quarter. WCM Investment Management LLC now owns 210,469 shares of the biopharmaceutical company’s stock valued at $7,686,000 after buying an additional 8,256 shares in the last quarter. CWM LLC increased its position in shares of Ultragenyx Pharmaceutical by 1,171.2% during the 2nd quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 3,818 shares in the last quarter. Finally, Aberdeen Group plc increased its position in shares of Ultragenyx Pharmaceutical by 4.6% during the 2nd quarter. Aberdeen Group plc now owns 501,056 shares of the biopharmaceutical company’s stock worth $18,218,000 after purchasing an additional 22,152 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.